1. Introduction {#s0005}
===============

The assessment of structural changes in the brain is made clinically by visual ratings of brain atrophy according to established visual rating scales. They offer an efficient and inexpensive method of quantifying the degree of atrophy and can help to improve the specificity and sensitivity of dementia diagnoses ([@bb0085]; [@bb0265]). However, there are limitations associated with visual ratings of atrophy, which may explain why they are still not widely used in the clinical routine. First, the ratings are inherently subjective which means that the agreement between two radiologist might be low if they have not had sufficient training ([@bb0085]). Second, in order to achieve adequate reliability the radiologist needs to be experienced and regularly perform ratings for the reproducibility not to drop ([@bb0020]). Third, the ratings are relatively time consuming and tedious. It takes a few minutes per image ([@bb0260]), depending on rating scale and level of rating experience. While this amount of time may be feasible in most clinical settings, it does not easily allow studying large imaging cohorts of potentially thousands of images. An automatic method would remove the inter- and intra-rater variability and eliminate the time-consuming process of rating.

Amongst the most commonly used visual rating scales---both in research and in clinical routine---are Scheltens\' Medial Temporal Atrophy (MTA) scale ([@bb0220]), Koedam\'s scale for Posterior Atrophy (PA) ([@bb0125]) and the frontal subscale of Global Cortical Atrophy (GCA-F) proposed by Pasquier ([@bb0225]; [@bb0185]). These scales each assess the atrophy in a specific region of the brain from Magnetic Resonance Imaging (MRI) or Computer Tomography (CT) images, and details about these scales can be seen in [Table 1](#t0005){ref-type="table"} with illustrative examples in [Fig. 1](#f0005){ref-type="fig"}. These scales have previously been validated by quantitative neuroimaging techniques used in research ([@bb0010]; [@bb0025]; [@bb0260]; [@bb0170]; [@bb0055]). MTA ratings have been shown to be significantly (anti-)correlated with hippocampal volume and width of the temporal horn ([@bb0010]; [@bb0025]; [@bb0260]). [@bb0170] found statistical differences in parietal cortex between PA ratings both in volumes of specific posterior gray matter regions, and using voxel-based morphometry ([@bb0170]). Further, the GCA-F scale has been shown to reliably reflect atrophy in the frontal cortex using both volumetrics and surface-based analysis ([@bb0055]). Some studies have explicitly compared diagnostic ability of using regional cortical volume and thickness measures as opposed to visual ratings in dementia cohorts, showing improved discrimination when using cortical measures ([@bb0010]; [@bb0280]). However, in cases where a neuroimaging software fails to extract volumetric information (e.g. due to presence of image artifacts or an odd scanning protocol) it would not be feasible---nor possible---to manually correct this error in a clinical situation. Yet, it is likely that the radiologist would still be able to make visual atrophy ratings of those images.Table 1Description of Scheltens\' MTA scale, Pasquier\'s frontal GCA subscale (GCA-F) and Koedam\'s PA scale. Abbreviations: Posterior cingulate sulcus (PCS); Parieto-occipital sulcus (POS); Precuneus (PRE); Hippocampus (HC).Table 1RatingMTA ([@bb0220])GCA-F ([@bb0185])PA ([@bb0125])0NormalNo atrophyNo atrophy1Widening of choroid fissure.Mild sulcal atrophy in frontal lobe.Mild widening of PCS and POS, mild atrophy of PRE and parietal lobes.2Increased widening of choroid fissure, widening of temporal horn, decreased height of HC.Moderate sulcal atrophy in frontal lobe.Substantial widening of PCS and POS, substantial atrophy of PRE and parietal lobes.3Increased widening of choroid fissure and temporal horn, further decreased heigth of HC.Severe sulcal atrophy in frontal lobe.Evident widening of PCS and POS, end-stage atrophy of PRE and parietal lobes.4Further decreased height of HC.----Rating slice(s)Single coronal slice.Multiple axial slices.Multiple slices, all anatomical planes.Fig. 1Examples of Scheltens\' MTA scale ([@bb0220]), Pasquier\'s frontal subscale of GCA ([@bb0185]), and Koedam\'s PA scale ([@bb0125]). The MTA ratings are done in the coronal plane, GCA-f in the axial plane, and PA ratings are based on assessments of all three planes. The area between the dashed lines in the left images indicates the slices assessed by a radiologist for the GCA-F and PA scales, while it shows the single slice assessed for MTA. The red boxes indicate the regions assessed for each rating scale.Fig. 1

A few automatic (or semi-automatic) methods to quantify medial temporal atrophy---besides volumetrics---have previously been proposed. Two of them involve planimetrics based on manual delineation of hippocampus and surrounding structures that are combined into a single score of medial temporal atrophy ([@bb0300]; [@bb0165]). While these methods assess almost the same structures as Scheltens\' MTA scale, the different scales are not interchangeable and do not necessarily reflect the same atrophy patterns. Another study recently reported an automatic method that is trained on radiologist ratings which predicts MTA scores based on volumetric measures extracted from the MRI image ([@bb0160]). Volumetric measures of brain regions can not be extracted from most CT images nor do they retain any information regarding the shape of the structures. It is reasonable to assume that the shapes are important since the visual MTA rating is done on a single slice, from which it is not possible to estimate the hippocampal volume.

Deep learning---a branch of machine learning---has recently generated impressive results in several fields, such as speech recognition, text semantics, image recognition and genomics ([@bb0135]). Convolutional neural networks (CNN\'s) have already been substantially applied in medical image analysis (for recent reviews, see ([@bb0230]; [@bb0145])). In neuroimaging, deep neural networks have been used successfully for automatic methods of skull stripping ([@bb0215]; [@bb0120]), brain age prediction ([@bb0035]), brain segmentation ([@bb0030]), PET image enhancement ([@bb0270]) and brain tumor segmentation ([@bb0200]; [@bb0295]) to name a few. In dementia research, several studies have investigated brains of patients with Alzheimer\'s disease (AD) using deep learning and shown impressive diagnostic abilities ([@bb0100]; [@bb0195]; [@bb0245]; [@bb0150]). A Recurrent Neural Network (RNN) is an artificial neural network that has an internal state (or "memory") and is useful when processing sequential data, such as words in a sentence or frames in a video ([@bb0135]; [@bb0040]). RNN\'s have previously been combined with CNN\'s to segment MRI images, where the addition of an RNN module helped to leverage adjacent slice dependencies ([@bb0290]; [@bb0205]).

In this study, we aimed to develop an automatic algorithm based on convolutional and recurrent neural networks that provides fast, reliable, and systematic predictions of established visual ratings scales of atrophy of brain regions often affected in dementia: the MTA, GCA-F and PA scales. The models are trained on a large set of MRI images that have been rated by an experienced neuroradiologist. This method is atlas-free and requires minimum amount of setup and third-party software. We plan to present the proposed algorithm as a freely available software targeted towards neuroimaging researchers.

2. Material and methods {#s0010}
=======================

2.1. MRI data and protocols {#s0015}
---------------------------

Two different dementia cohorts of MRI images were included in this project: Alzheimer\'s Disease Neuroimaging Initiative (ADNI) and a clinical cohort with images from the memory clinic at Karolinska University Hospital (referred to as *MemClin* from here on). Informed consent was obtained for all participants, or by an authorized representative of theirs.

Individuals in the MemClin cohort consisted of patients clinically diagnosed between 2003 and 2011 with AD according to the ICD-10 criteria, or frontotemporal dementia (FTD) using the diagnostic criteria by [@bb0180]. Brain images of these patients had been visually rated by neuroradiologist Lena Cavallin (L.C.) in previous studies by our group focused on AD and FTD, with the exclusion criteria of patients having history of traumatic brain injury (\<1%) or insufficient quality of the MRI scan (\<1%, not possible to visually rate) ([@bb0065]; [@bb0140]). An additional exclusion criterion in this study was failed automatic registration using FSL of images possible for a radiologist to visually rate (2.6%). All participants underwent a T~1~-weighted MRI scan at the Radiology Department of Karolinska University Hospital in Stockholm, Sweden.

Data used in the preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#ir0015}). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer\'s disease (AD). For up-to-date information, see [www.adni-info.org](http://www.adni-info.org){#ir0020}. A majority of the participants in the ADNI cohort were scanned multiple times within a few weeks---often in the same day. A subset of participants were scanned both in 1.5 T and 3 T machines.

All available images with an associated visual atrophy rating performed by a neuroradiologist were used in this study: a total of 5271 images. They were obtained from 117 different scanners (112 in ADNI and 5 in MemClin, see Supplementary Data for detailed description of scanner protocols), where all except 36 scans were acquired using a 3D MRI protocol. The MemClin image data was collected as part of the clinical routine with standard---but not strictly harmonized---MRI protocols, including updates and protocol changes over time. Thus, the MemClin data largely resembles the MRI variability present in clinics, whereas the ADNI data does not due to extensive efforts in harmonizing the MRI protocols across scanners.

We used theHiveDB database system ([@bb0175]) for data management during the development of the algorithm, which will become part of theHiveDB\'s automated activity system.

2.2. Human ratings {#s0020}
------------------

An experienced neuroradiologist (L.C.) visually rated 2350 T~1~-weighted MRI images over the course of 16 months with no prior knowledge of age, sex, or diagnosis. For ADNI subjects scanned more than once within a few weeks (i.e. within the same ADNI time-point), only one of these images was rated by the radiologist and the additional image(s) were labeled with the same rating. The distribution of L.C.\'s MTA, PA and GCA-F ratings are shown in [Table 2](#t0010){ref-type="table"}. Many of the ADNI ratings have been analyzed and reported in previous studies ([@bb0065]; [@bb0050]; [@bb0055]; [@bb0060]; [@bb0280]). All visual ratings of MTA, PA and GCA-F were based on T~1~-weighted MRI images, and illustrative examples of the ratings can be seen in [Fig. 1](#f0005){ref-type="fig"}. The images were aligned with AC-PC (the anterior and posterior commissures) by the radiologist if the protocol allowed for it ([@bb0020]). The MTA ratings were made in a single coronal slice, just behind the amygdala and mammillary bodies. The GCA-F ratings were based on multiple axial slices, whereas the PA scores were based on slices in all three planes.Table 2The rating distribution of the images used in the study. The "Images" column refers to how many *unique* images that were rated by the radiologist at least once. Both the left and right MTA ratings are presented in the "MTA" column in the Table.Table 2CohortImagesMTAGCA-FPA0123401230123ADNI1966425158111475552241449468490118861115710MemClin384232652961394527989142210127434Total2350448184614436942691728557632139873820014

To get an idea of the variability in the human ratings used for training AVRA, we studied the intra-rater agreement in a subset of 244 images that had been rated 2--4 times with at most 16 months from the first to the last rating session by L.C. To be consistent with the computer training and evaluation procedure, we compared the latest rating to a previous one. If there were more than two ratings, the previous rating was chosen randomly.

2.3. Computer ratings {#s0025}
---------------------

The motivation behind the proposed model architecture was to mimic how a neuroradiologist would process an MRI image: to scroll through the brain volume slice-by-slice looking for the "correct" slice(s) to base the rating on. A human rater assesses images acquired using different scanners, vendors and protocols without any need for substantial preprocessing such as segmentation, intensity normalization, non-linear registrations or skull-stripping. To better mimic the clinical situation (and to keep the number of time consuming preprocessing steps that can potentially fail to a minimum) we trained AVRA to rate images with as little preprocessing as possible. The main difference between AVRA\'s and a human rater is that AVRA\'s ratings are continuous instead of discrete.

All code in this project was developed in Python 3.4.3 using the deep learning framework PyTorch 1.0 ([@bb0190]). The training of AVRA was done on GPU\'s for computational efficiency. To obtain an estimate of the time to run a single case when run on a "regular" computer, we processed and timed five individual cases using CPU only (Intel®Core ™i7-8700k, 32GB DDR-4) without GPU support.

### 2.3.1. Preprocessing {#s0030}

The only preprocessing included in our method is the registration of all brains to the MNI standard brain using FSL FLIRT 6.0 (FMRIB\'s Linear Image Registration Tool) ([@bb0115]; [@bb0110]; [@bb0080]). This rigid transform is computed with 6 degrees of freedom (i.e. rotation and translation only) and is used to automatically AC-PC align each brain and conform all images to the same voxel size (1x1x1mm^3^) and input dimension (182x218x182). The AC-PC aligned images are cropped to remove excess space outside the brain and redundant slices not part of the ratings scale (as indicated in [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}). The center-voxel of the cropped images depended on the rating scale. For the MTA ratings, 22 coronal slices of the dimension 128 mm × 128 mm are input to the model---enough to ensure that the "correct" rating slice is included. The GCA-F ratings are done on multiple axial slices so each volume is cropped to 160 mm × 192 mm × 40 slices, with 2 mm slice thickness. The PA model requires slices from all three anatomical planes. From each MRI image a smaller volume of 128 mm × 128 mm × 128 mm was extracted from the parietal lobe, sufficiently large to include all relevant structures in the parietal cortex. From this cropped volume 37 axial, 28 coronal and 34 sagittal slices with 2 mm slice thickness (i.e. 99 slices in total) were used as input to the model. Since the distribution of raw voxel values was very different---particularly between 1.5 T and 3 T images---all cropped volumetric images were normalized to have a zero variance and mean.Fig. 2A sketch of the architecture of AVRA, with the example of a GCA-F prediction. Briefly, each slice is processed through the residual attention network and the extracted features are passed to a 2-layer Long-Short Term Memory (LSTM) network. Once all MRI slices have propagated through these two stages, a fully connected network (FC) makes a prediction of the visual atrophy rating. The MTA and PA models followed the same structure.Fig. 2

### 2.3.2. Model architectures {#s0035}

The overall structure of the models is shown in [Fig. 2](#f0010){ref-type="fig"} and can be split into three parts. First, relevant features from a single slice are extracted using a Residual Attention Network ([@bb0275]), detailed in [Fig. 3](#f0015){ref-type="fig"}. It combines the abilities from residual learning ([@bb0090]), which can allow for even deeper models, and attention models that can "focus" spatially on images---particularly useful for visual ratings since they are based on regional atrophy ([@bb0285]; [@bb0005]). Our implementation is a slimmed version of the original, with the same depth but a smaller number of filters in each layer to reduce memory usage and computation time. Initial experiments showed no noticeable performance reduction on the validation set compared to using a larger network. Second, the features are reshaped to a 1D vector and fed to an RNN, which consists of a two-layer Long-Short Term Memory (LSTM) network with 256 hidden nodes ([@bb0095]; [@bb0070]). The LSTM modules are expected to "remember" relevant features seen in previous slices and update its state ("memory") when it is exposed to a slice containing useful information for the rating. Finally, when slice 0, 1, ..., (*n* − 1) have been propagated through the network, the final output from the second LSTM module *h*~*n*~^(2)^ is used to make a linear prediction of the visual rating. All three models share the same network architecture except for the size of the input vector fed to the LSTM network, as that is dependent on the input size of the MRI slices.Fig. 3A sketch of the residual attention net used to extract features from individual MRI slices, where the flattened output is fed to the RNN. The downsampling block consists of stacking maxpooling operations followed by a residual block. The upsamling is performed with bilinear interpolations of the output of a residual block. The "+", "x", and "S-shaped" symbols denote element-wise summation, multiplication and the sigmoid function, respectively. The flow chart is adapted from ([@bb0275]).Fig. 3

For comparison, we trained a VGG16 network ([@bb0235]) without the RNN part, where the 3D volumes are treated as multi-channel 2D images. That is, for the MTA model we input one "22-channel" image to the CNN once instead of 22 single-slice images.

### 2.3.3. Training {#s0040}

For training and evaluation, the dataset was randomly split into a training and a hold-out test set, where 20% of all subjects were assigned to the test set. On the remaining images in the training set we applied 5-fold cross validation for hyper-parameter tuning for each rating scale. The five trained models were used together as an ensemble classifier evaluated on the test set, where the average prediction was considered the final rating.

The models were trained for 200 epochs using backpropagation and optimized through stochastic gradient descent (SGD) with cyclic learning rate to maximize the probability of predicting the radiologist\'s rating ([@bb0155]; [@bb0105]). The training set was randomly split into minibatches, each containing 20 MRI images, and the weights were updated to minimize the mean-squared error between the automatic and the integer ratings by L.C. We employed data augmentation in the training process of the network to reduce the risk of overfitting to the training set. This included random cropping (within ±10mm off the center voxel), scaling, left/right mirroring, and randomly selecting N4ITK inhomogeniety corrected images instead of the original file ([@bb0250]). Due to the imbalance of ratings in the dataset we employed random oversampling of images with less frequent ratings, which has been shown to improve the prediction performance of CNN\'s ([@bb0015]). For ADNI subjects that had multiple scans for a single timepoint, a scan was selected randomly for each minibatch.

2.4. Analyses metrics {#s0045}
---------------------

The visual rating scales are subjective measures by definition. Consequently, there are no objective ground truth ratings available. In most studies, the performance of a rater is reported in kappa statistics---a group of measures that can quantify the level of agreement between two sets of discrete ratings---but there is no single metric always reported. To make our results comparable to previous findings, we present our results with Cohen\'s weighted kappa (*κ*~*w*~), which has been used in several previous rating studies ([@bb0125]; [@bb0280]; [@bb0020]; [@bb0025]; [@bb0055]; [@bb0060]; [@bb0255]), as well as accuracy and the Pearson correlation coefficient (*ρ*). The agreement between two sets of ratings is referred to as *inter*-rater agreement if the sets were assessed by different raters, and *intra*-rater agreement if a single radiologist rated the set twice.

3. Results {#s0050}
==========

For the 244 images rated more than once by the radiologist the intra-rater agreement *κ*~*w*~ and accuracy for MTA (left) were: *κ*~*w*~ = 0.83, acc = 76%; MTA (right): *κ*~*w*~ = 0.79, acc = 70%; GCA-F: *κ*~*w*~ = 0.46, acc = 71%; PA *κ*~*w*~ = 0.65, acc = 72%. Ratings made only 1 week apart showed substantially better intra-rater agreement (see [@bb0060] entry in [Table 3](#t0015){ref-type="table"}). These results provide an estimate of the "human-level agreement"---i.e. approximate levels of agreement our models should be able to achieve by training on the available cohort due to rating inconsistencies over 16 months. Since there are no random elements in the evaluation process of a brain image, the "intra-rater" agreement of AVRA is inherently *κ*~*w*~ = 1.Table 3Previous studies reporting weighted kappa (*κ*~*w*~) values for intra- and inter-rater agreements together with the test set agreement between L.C. and AVRA (in bold text), and L.C and VGG16 as a reference. The interval given refers to the minimum and maximum *κ*~*w*~ value reported in the referenced study. The *N* column refers to the number of images used for the intra- and inter-rater assessment (if two values are given the number of images rated were different for the intra- and the inter-rater analysis). ^∗^ denotes if L.C. (whose ratings was used for training in this study) was one of the raters in the reported agreements.Table 3StudyScale*N*Intra-rater agreement (*κ*~*w*~)Inter-rater agreement (*κ*~*w*~)[@bb0020]MTA1000.83--0.94^∗^0.72--0.84^∗^[@bb0025]MTA1000.84--0.85^∗^--[@bb0280]MTA1000.93^∗^--[@bb0255]MTA20/500.79--0.840.6--0.65^∗^[@bb0060]MTA1200.89--0.94^∗^0.70--0.71^∗^[@bb0125]MTA29/1180.91--0.950.82--0.90VGG16MTA46410.58--0.59^∗^**AVRAMTA46410.72--0.74**^∗^[@bb0125]PA29/1180.93--0.950.65--0.84[@bb0060]PA1200.88^∗^0.88^∗^VGG16PA46410.63^∗^**AVRAPA46410.74**^∗^[@bb0055]GCA-F1000.70^∗^0.59^∗^[@bb0060]GCA-F1200.83^∗^0.79^∗^VGG16GCA-F46410.56^∗^**AVRAGCA-F46410.62**^∗^

Our models predicted continuous rating scores of an image, based on training from discrete ratings by L.C. We rounded AVRA\'s ratings to the nearest integer to be able to compare the rating consensus in terms of accuracy and kappa statistics. The agreements between the radiologist\'s and AVRA\'s (as well as the VGG networks\') ratings on the hold-out test set are summarized in [Table 3](#t0015){ref-type="table"} together with previously reported *κ*~*w*~ values of inter- and intra-rater agreements. The inter-rater agreement *k*~*w*~, Pearson correlation *ρ*, and accuracy on the test set for MTA (left): *κ*~*w*~ = 0.74, *ρ* = 0.88, acc = 70%; MTA (right): *κ*~*w*~ = 0.72, *ρ* = 0.88, acc = 70%; GCA-F: *κ*~*w*~ = 0.62, *ρ* = 0.71, acc = 84%; PA: *κ*~*w*~ = 0.74, *ρ* = 0.85, acc = 83%. These agreement levels were similar to previously reported in studies, see [Table 3](#t0015){ref-type="table"}. The naive VGG16 implementations showed lower inter-rater agreements with the radiologist compared to AVRA.

To increase interpretability and understanding of the models, we computed gradient-based sensitivity maps of images in the test set based on the SmoothGrad method ([@bb0240]). These indicated how influential individual voxels were in the rating prediction, which we can apply to verify that the network identified the correct features. Examples of AVRA\'s rating predictions for each scale are shown in [Fig. 4](#f0020){ref-type="fig"}. As can be observed, the MTA sensitivity maps were generally focused only around the area of the hippocampus and the inferior lateral ventricle in ∼± 3 slices from the "correct" rating slice. The sensitivity maps in other more posterior and anterior slices were close to zero. The GCA-F maps were more diffused, but the greatest magnitudes were primarily seen in the sulci of the frontal lobe. The PA maps were mainly visible in the parietal lobe and in the sagittal plane, with the greatest magnitudes appearing in parieto-occiptal sulcus and precuneus.Fig. 4Examples of sensitivity maps for the MTA, GCA-F and PA scale, respectively. These maps indicate the influence each voxel had in AVRA\'s rating. The particular slices displayed were chosen manually as representative images for each rating scale.Fig. 4

The average time to process a single image using AVRA without GPU support was 48 s, where the majority of the processing time was spent on the AC-PC alignment using FSL FLIRT.

4. Discussion {#s0055}
=============

We have developed a tool for automatic visual ratings of atrophy (AVRA) that is fast, systematic and robust. AVRA is trained on a large set of images rated by an expert neuroradiologist using the established clinical assessment measures of Scheltens\' MTA scale, Pasquier\'s GCA-F scale and Koedam\'s PA scale with agreement levels similar to that between two experienced radiologists. This tool runs in under 1 min on a regular computer, which enables automatically rating thousands of images in a couple of hours. The main advantage of an automatic model is the absence of randomness, which can improve rating consistency between different clinics, research groups and cohorts. Thus, AVRA can increase the use of visual ratings in research, and has---after extensive validation---the potential to function as a clinical aid in the future.

The rating agreements between AVRA\'s and the radiologist\'s ratings were considered *substantial* (i.e. between 0.6 and 0.8) according to the often cited paper by [@bb0130] ([@bb0130]). The agreements were close to the "human-level agreements" in this study (i.e. the agreement between the multiple L.C. ratings of the same image). This was reasonable since a model trained on imperfect labels due to rating inconsistency can never achieve perfect agreement. AVRA\'s ratings agreed more with the radiologist ratings than the VGG16 models\' did. A recurrent CNN architecture might thus be particularly suitable for visual rating predictions, but we can not say from these results if it was the residual modules, the attention components, or the LSTM cells---all used in AVRA but not in the VGG16 models---that had the greatest positive impact on the performance. Another contributing factor may be the wide difference in the number of trainable parameters between AVRA (1.5 M) and VGG16 (65 M) that makes AVRA less prone to overfit on the training data.

The automatic model presented by Lötjönen and colleagues (2017) is, to our knowledge, the only software that also attempts to predict scores based on clinical visual rating scales ([@bb0160]). It is based on volume measures of hippocampus and surrounding structures, whereas AVRA predicts the ratings directly from the voxel intensity values. This makes our proposed method promising to also work on MRI images with large slice thickness and CT images, from which volumes generally cannot be computed. The fact that CT is a cheaper and more commonly used imaging modality than MRI in the clinics speaks in favor of using convolutional neural networks over volumetrics for automatic predictions of visual ratings ([@bb0045]). No *κ*~*w*~ values are reported in ([@bb0160]), but they provided correlation coefficients between radiologist and computer ratings for the MTA scale as 0.86 (left) and 0.85 (right). AVRA showed a similar magnitude of correlation for the MTA scale on the hold-out test set: *ρ* = 0.88.

Frequently, it is difficult for a radiologist to decide between two scores, and in a clinical situation the level of atrophy is often described as "the left MTA is between 2 and 3" for instance. This nuance might be important information for the physician diagnosing dementia, but in research single integer scores have typically been used following the original definitions of the rating scales. Previous attempts of (semi-)automatic atrophy measures have output a continuous measure ([@bb0300]; [@bb0165]; [@bb0075]; [@bb0160]). The main advantages of using a continuous measure of atrophy are 1) atrophy evolves continuously and thus it is reasonable to describe its degree through a continuous measure, and 2) it provides more detailed information about the severity of the atrophy. The latter point is for instance particularly useful to track disease progression and could allow us to establish more sensitive cut-off values for different diagnoses.

In [Fig. 5](#f0025){ref-type="fig"} we show some examples between AVRA\'s continuous and the radiologist discrete ratings in the important diagnostic interval between MTA = 2 and MTA = 3. When studying these images again post AVRA\'s ratings, the radiologist only assessed that the images originally rated MTA = 2 with associated AVRA scores of 2.6--3.0 to be wrongly rated. They would be re-rated as MTA = 3, i.e. closer to AVRA\'s score. The image scored MTA = 2 (radiologist) and MTA = 2.4 (AVRA) was described as a case between 2 and 3, which may illustrate the usefulness of continuous ratings. However, we noticed that in two of the most disagreeing ratings (L.C.: MTA = 3, Avra: MTA = {2.0, 2.2}) the individuals had an adhesion between the hippocampus and the cerebral white matter. These cases are not frequent, and the rating disagreements in [Fig. 5](#f0025){ref-type="fig"} indicate that AVRA did not learn to correctly adjust the score for the presence of adhesions.Fig. 5Comparison between AVRA\'s continuous ratings and the neuroradiologist\'s discrete ratings of the same images. *Rows*: MRI slices with MTA on the right side of the image (side indicated by the red squares) rating of 2 (top) and 3 (bottom) given by neuroradiologist. *Columns*: corresponding continuous AVRA ratings. E.g., the second image from the left in the bottom row was given assessed to have a left MTA score of 3 by the neuroradiologist and 2.2 by AVRA. When the radiologist re-examined these cases the same ratings were given for all images, except for the three images on the right in the top row (Radiologist: 2, AVRA: 2.6, 2.8 and 3.0), which were instead given MTA scores of 3. The image rated 2 by L.C. and 2.4 by AVRA was described as a subject between 2 and 3.Fig. 5

One of the main motivations of having a computer rate brain atrophy instead of humans is its inherent perfect intra-rater agreement---the same image will be rated exactly the same regardless of when (and where) it is rated. A relevant question to ask is: why not let a computer segment and calculate e.g. hippocampal volumes instead of an MTA rating? We see two main motivations for this: First, CT, and some MRI protocols, have too large slice thickness that do not allow for extracting reliable volumetric information from the images. While not explicitly investigated in this project, the RNN component of AVRA (allowing us to extract information from the MRI slice-by-slice) makes it possible to process images with large slice thickness. Second, segmentation methods will---just as AVRA---fail in processing some cases, and for clinician to manually intervene and delineate structures would neither be feasible nor practical. If an automatic visual rating would fail the radiologist would be able to quickly perform their own visual rating, as is done today.

The sensitivity maps shown in [Fig. 4](#f0020){ref-type="fig"} suggested that the models were able to correctly identify relevant structures to base their ratings on. Particularly the sensitivity maps of the MTA model were typically not visible ±3mm from the "correct" rating slice, indicating that the employed recurrent CNN architecture used was able to correctly identify relevant slices and disregard redundant ones. The diffused sensitivity maps seen for the GCA-F scale was also observed in the quantitative validation study using surface-based analysis by [@bb0050], showing that frontal atrophy is also associated with temporal and posterior atrophy---at least in the ADNI cohort ([@bb0055]). [@bb0170] found, using VBM analysis, significant differences between PA ratings not only in the parietal lobe, but also in parts of the cerebellum, temporal lobe and the occipital lobe ([@bb0170]). Their study was also performed on a cohort with individuals with probable AD and subjective memory complaints, concluding that atrophy solely in the posterior cortex is an exception. The sensitivity maps from our PA model indicate that AVRA based the PA ratings on mainly the same regions. AVRA learns to how to predict a GCA-F or a PA score from an MRI image *only* based on previous human ratings. Thus, if e.g. frontal atrophy is strongly associated with atrophy in the temporal lobe, the model is likely to find it difficult to learn to only assess the frontal lobe in the GCA-F scale.

There are some limitations of the proposed algorithm. First, the models are solely based on the ratings by a single radiologist and thus assume that the ratings we trained the model on are "ground truth" labels. A model trained on these labels can therefore never be "better" than the rater. If the ratings have systematic errors the model will incorporate these. For instance, a rater might systematically look at the left medial temporal lobe when rating the MTA of the right hemisphere, which could influence (bias) the right hemisphere MTA score. If we train a model on these ratings, this bias would be learned by the model as well. Another approach would be to have multiple expert radiologists rate a set of images together or separately and use these labels as ground truth. However, it is not feasible to have multiple radiologist visually assess the large number of images necessary for training a deep neural network. If future studies want to use a neural network based on their own set of ratings, it should be possible to start from the pre-trained networks of AVRA and fine-tune the final classification layer(s) on the new ratings. This would require substantially fewer ratings, since the convolutional part would already have learned to extract relevant features from the images. The second limitation of the study are the small numbers of the highest GCA-F and PA ratings, which may increase the risk of "true" 3 score to be misclassified. Based on the results in [Fig. 6](#f0030){ref-type="fig"} this seems to be the case. As the diagnostic cut-off values for these ratings scales in AD diagnosis have been suggested as PA ≥ 1 and GCA-F ≥ 1 ([@bb0050]), the clinical implications of this may be minor even in the cases where the atrophy is rated as a 2 instead of a 3. These severe ratings are rare also in previous studies on dementia cohorts ([@bb0050]; [@bb0210]), so this will likely be an issue for any computerized method trained on radiologist ratings.Fig. 6Box plots of the difference between AVRA\'s continuous and the radiologist\'s discrete ratings of the same image (stratified by radiologist score) for the MTA (red), GCA-F (green), and the PA scale (blue). There were no images assigned a rating of GCA-F = 3 by the radiologist and only 1 image with PA = 3 in the test set, which explains the absence of boxes for these ratings.Fig. 6

The performance of AVRA was validated in a test set that was randomly sampled from the same cohorts as the training data set. This is a simpler test set than if the test set was from a different cohort with images acquired using other scanning parameters, which would better reflect the clinical setting. Further, since AVRA is evaluated on scores by the same radiologist that rated the training set, the agreement levels are expected to be lower if compared to an external rater. We are currently in the process of validating how the models would handle data acquired with different MRI protocols and the effect it would have on rating agreement.

5. Conclusion {#s0060}
=============

In this study, we have proposed an automatic method (AVRA) to provide visual ratings of atrophy according to Scheltens\' MTA scale, Koedam\'s PA scale, and Pasquier\'s frontal GCA scale. AVRA mimics the neuroradiologist\'s rating procedure and achieves similar levels of agreement to that between two experienced neuroradiologists---without any prior preprocessing of the MRI images. We plan to make AVRA freely available as a user-friendly software aimed towards neuroscientists.
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[^1]: Data used in preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#ir0005}). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>
